Lenalidomide reduces the percentage of myeloid progenitor cells, including CD34+CD71+ erythroid progenitor cells but increases the proportion of erythroid precursor cells (CD36+/-GlycoA+) in bone marrow of del(5q) MDS patients, indicating that lenalidomide limits the del(5q) pathological clones and recovers the non-del(5q) clones that exhibit improved erythroid differentiation properties [75]. This evidence concerns the gene CD34 and myelodysplastic syndrome.